IRIS UniCatt

Antonaci, Laura
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.663
EU - Europa 1.281
AS - Asia 1.179
SA - Sud America 213
Continente sconosciuto - Info sul continente non disponibili 59
AF - Africa 28
OC - Oceania 1
Totale 4.424
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.595
SG - Singapore 619
NL - Olanda 358
IT - Italia 246
CN - Cina 213
BR - Brasile 173
SE - Svezia 158
FR - Francia 156
DE - Germania 107
VN - Vietnam 86
IE - Irlanda 60
GB - Regno Unito 48
JP - Giappone 40
ID - Indonesia 35
CA - Canada 34
IN - India 31
PL - Polonia 26
HK - Hong Kong 24
RU - Federazione Russa 24
FI - Finlandia 22
BD - Bangladesh 20
TR - Turchia 20
MX - Messico 18
IQ - Iraq 17
AR - Argentina 15
KR - Corea 14
ES - Italia 11
RO - Romania 11
IR - Iran 10
AT - Austria 8
BE - Belgio 8
ZA - Sudafrica 8
LT - Lituania 7
PA - Panama 7
PK - Pakistan 6
UA - Ucraina 6
CH - Svizzera 5
EC - Ecuador 5
IL - Israele 5
JO - Giordania 5
OM - Oman 5
SA - Arabia Saudita 5
AE - Emirati Arabi Uniti 4
EG - Egitto 4
KZ - Kazakistan 4
UZ - Uzbekistan 4
VE - Venezuela 4
BG - Bulgaria 3
BO - Bolivia 3
BY - Bielorussia 3
CO - Colombia 3
CZ - Repubblica Ceca 3
MA - Marocco 3
PH - Filippine 3
PY - Paraguay 3
TN - Tunisia 3
UY - Uruguay 3
CI - Costa d'Avorio 2
CL - Cile 2
CR - Costa Rica 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
JM - Giamaica 2
KE - Kenya 2
LA - Repubblica Popolare Democratica del Laos 2
ME - Montenegro 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
AZ - Azerbaigian 1
BH - Bahrain 1
DZ - Algeria 1
GR - Grecia 1
GY - Guiana 1
HN - Honduras 1
HR - Croazia 1
HT - Haiti 1
KG - Kirghizistan 1
KH - Cambogia 1
LB - Libano 1
LU - Lussemburgo 1
LY - Libia 1
NG - Nigeria 1
NP - Nepal 1
PE - Perù 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SY - Repubblica araba siriana 1
TG - Togo 1
TT - Trinidad e Tobago 1
UG - Uganda 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.367
Salva come PNG Salva come JPEG
Città #
Singapore 370
Amsterdam 348
Ashburn 200
San Jose 192
Chandler 190
New York 88
Rome 68
Beijing 49
Los Angeles 48
Dublin 46
Tokyo 35
Hefei 34
Jakarta 34
Lauterbourg 31
Milan 31
Munich 31
Tukwila 29
Dallas 28
Boston 26
Ho Chi Minh City 26
Frankfurt am Main 25
Marseille 25
Hong Kong 23
Princeton 21
San Mateo 19
Hanoi 18
Santa Clara 18
Denver 17
Warsaw 17
Buffalo 16
São Paulo 16
Chicago 15
Montreal 15
Paris 15
The Dalles 15
Atlanta 14
Moscow 14
Nuremberg 14
Orem 14
Seoul 14
Helsinki 12
Houston 11
Palermo 11
Ann Arbor 10
Bremen 9
Council Bluffs 9
London 9
Baghdad 8
Boardman 8
Düsseldorf 8
Kent 8
Mexico City 8
Portsmouth 8
Shanghai 8
Ankara 7
Brussels 7
Wilmington 7
Belo Horizonte 6
Brooklyn 6
Hyderabad 6
Johannesburg 6
Memphis 6
Menlo Park 6
Phoenix 6
Poplar 6
Seattle 6
Stockholm 6
Toronto 6
Washington 6
Amman 5
Brasília 5
Brescia 5
Chennai 5
Dhaka 5
Fairfield 5
Falkenstein 5
Haiphong 5
Kish 5
Lappeenranta 5
Salvador 5
Wroclaw 5
Ahmedabad 4
Augusta 4
Bexley 4
Charlotte 4
Columbus 4
Da Nang 4
Florence 4
Gustavo Adolfo Madero 4
Las Vegas 4
Pittsburgh 4
Redwood City 4
Rio de Janeiro 4
Salt Lake City 4
Turku 4
Almaty 3
Ancona 3
Andover 3
Bar Harbor 3
Biên Hòa 3
Totale 2.600
Salva come PNG Salva come JPEG
Nome #
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 506
Early neurological signs in infants identified through neonatal screening for SMA: do they predict outcome? 164
Different trajectories in upper limb and gross motor function in spinal muscular atrophy 161
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 157
Age related treatment effect in type II Spinal Muscular Atrophy pediatric patients treated with nusinersen 157
Predominant distal muscle involvement in spinal muscular atrophy 151
Early treatment of type II SMA slows rate of progression of scoliosis 143
Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial 137
Nusinersen efficacy data for 24-month in type 2 and 3 spinal muscular atrophy 136
Nusinersen in pediatric and adult patients with type III spinal muscular atrophy 133
MRI patterns of muscle involvement in type 2 and 3 spinal muscular atrophy patients 132
A critical review of patient and parent caregiver oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in spinal muscular atrophy 129
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial 128
Does albuterol have an effect on neuromuscular junction dysfunction in spinal muscular atrophy? 123
Sleep disorders in spinal muscular atrophy 119
New therapies for spinal muscular atrophy: where we stand and what is next 119
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 117
Clinical Variability in Spinal Muscular Atrophy Type III. 116
Revised upper limb module in type II and III spinal muscular atrophy: 24-month changes 116
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 115
Development of an academic disease registry for spinal muscular atrophy 115
Communicative development inventory in type 1 and presymptomatic infants with spinal muscular atrophy: a cohort study 114
Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis 109
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 106
P.222Long term progression in type II spinal muscular atrophy: a retrospective observational study 105
Profile of cognitive abilities in spinal muscular atrophy type II and III: what is the role of motor impairment? 102
Long term follow-up of scoliosis progression in type II SMA patients 101
Long-term progression in type II spinal muscular atrophy: A retrospective observational study 97
Correction to: Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study (Neurology and Therapy, (2023), 12, 2, (543-557), 10.1007/s40120-023-00444-1) 96
Patient and parent oriented tools to assess health-related quality of life, activity of daily living and caregiver burden in SMA. Rome, 13 July 2019 96
Caregivers’ Expectations on Possible Functional Changes following Disease-Modifying Treatment in Type II and III Spinal Muscular Atrophy: A Comparative Study 88
Sometimes they come back: New and old spinal muscular atrophy adults in the era of nusinersen 85
Diagnostic journey in Spinal Muscular Atrophy: Is it still an odyssey? 82
Italian validation of the SMA independence scale–upper limb module 41
Neurodevelopmental and mental disorders in children with type I and presymptomatic spinal muscular atrophy 12
Longitudinal Assessment of 4-Year HFMSE Changes in SMA II and III Patients Treated With Nusinersen 9
Expressive language and social communication abilities in children with spinal muscular atrophy type 1 7
Totale 4.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.904
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.904
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022227 0 4 5 44 18 8 6 31 18 16 38 39
2022/2023537 50 78 31 86 29 66 30 50 75 5 20 17
2023/2024383 7 82 12 35 12 80 28 23 1 30 34 39
2024/2025796 12 14 53 41 70 42 46 24 119 86 161 128
2025/20262.257 252 38 110 260 364 439 341 80 100 124 118 31
2026/2027166 60 106 0 0 0 0 0 0 0 0 0 0
Totale 4.424